rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

News

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Topics • Strategy

After Pharma’s Patent Cliff

Top-Feature

Bio-Rad Laboratories

Anchored in Sustainability

Interview

The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

SchüllerConsulting

Immedica Pharma AB

rare disease

Immedica to Acquire Biopharma Company Marinus

Pfizer Doubles Dublin Biologicals Capacity

After Pharma’s Patent Cliff

Top-Feature

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Leading the way. Driving results.

Brenntag Downsizes Management Board, Retains Both Divisions

Advanced Recycling Conference 2025: New Paths to the Circular Economy

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

API Manufacturing

Driving Sustainability Through Collaboration

Leading Transformation

Anchored in Sustainability

Interview

Leading Transformation

Newsletter & e-edition